Briakinumab Biosimilar – Research Grade: APC

Briakinumab Biosimilar – Research Grade

Allophycocyanin (APC)

CD30

n/a

Human IgG1(E356D/M358L)-Kappa

Receptor tyrosine-protein kinase erbB-2, MLN 19, HER2, HER2/neu

CHO Cells

Human

Detects human ErbB2. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Our Briakinumab biosimilar is for research use only (RUO).

Briakinumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Briakinumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary).

0.2 mg/ml

This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.

Flow Cytometry, IHC

Red Laser (650 nm). Each investigator should determine their own optimal working dilution for specific applications.